Search

Since the first approval of the anti-CD3 recombinant monoclonal antibody (mAb), muromonab-CD3, a mouse antibody for the prevention of transplant rejection, by the US Food and Drug Administration (FDA) in 1986, mAb therapeutics have become increasingly important to medical care. A wealth of information about mAbs regarding their structure, stability, post-translation modifications, and the relationship between modification and function has been reported. Yet, substantial resources are still required throughout development and commercialization to have appropriate control strategies to maintain consistent product quality, safety, and efficacy. A typical feature of mAbs is charge heterogeneity, which stems from a variety of modifications, including modifications that are common to many mAbs or unique to a specific molecule or process. Charge heterogeneity is highly sensitive to process changes and thus a good indicator of a robust process. It is a high-risk quality attribute that could potentially fail the specification and comparability required for batch disposition. Failure to meet product specifications or comparability can substantially affect clinical development timelines. To mitigate these risks, the general rule is to maintain a comparable charge profile when process changes are inevitably introduced during development and even after commercialization. Otherwise, new peaks or varied levels of acidic and basic species must be justified based on scientific knowledge and clinical experience for a specific molecule. Here, we summarize the current understanding of mAb charge variants and outline risk-based control strategies to support process development and ultimately commercialization. [ABSTRACT FROM AUTHOR]

This study presents an approach for targeted comminution of component mixtures within a wet-operated stirred media mill. In the first step, a general understanding of the interactions between individual components on the grinding result with mixtures could be gained with basic experiments and following our former research work. In particular, a protective effect of the coarser particles on the fines could be elucidated. These findings were used to develop a process for the production of a battery slurry containing fine ground silicon particles as well as dispersed carbon black and graphite particles. By a tailored sample preparation applying a combination of particle dissolution and separation, the particle size distributions of carbon black and graphite particles were analyzed separately within the produced battery slurries. Based on the selective particle size analysis, the slurry preparation could be transferred from a complex multistage batch process using a dissolver to a stirred media mill, which was finally operated in a continuous one-passage mode. The prepared slurries were subsequently further processed to silicon-rich anodes using a pilot scale coating and drying plant. Afterward, the produced anodes were electrochemically characterized in full cells. The cell results prove a comparable electrochemical behavior of anode coatings derived from a dissolver- or mill-based slurry production process. Therefore, we could demonstrate that it is possible to integrate the mixing process for the production of multicomponent slurries into the comminution process for the preparation of individual materials upstream. Even with nearly identical starting sizes of their feed materials, the targeted particle size distributions of the single components can be reached, taking into account the different material-dependent particle strengths and sequential addition of single components to the multicomponent comminution process. [ABSTRACT FROM AUTHOR]